Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome

Recruiting

Phase 1

SX-682Study of SX-682 Alone and in Combination with Oral or Intravenous Decitabine in Subjects with Myelodysplastic Syndrome

Sponsor:

Syntrix Biosystems, Inc.

Code:

NCT04245397

Conditions

Myelodysplastic Syndromes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SX-682

Decitabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-18. This information was provided to ClinicalTrials.gov by Syntrix Biosystems, Inc. on 2024-11-25.